Literature DB >> 31262759

Nucleoside Analogs with Antiviral Activity against Yellow Fever Virus.

Keivan Zandi1, Franck Amblard1, Sarah Amichai1, Leda Bassit1, Sijia Tao1, Yong Jiang1, Longhu Zhou1, Olivia Ollinger Russell1, Seema Mengshetti1, Raymond F Schinazi2.   

Abstract

Yellow fever virus (YFV) is a human Flavivirus reemerging in parts of the world. While a vaccine is available, large outbreaks have recently occurred in Brazil and certain African countries. Development of an effective antiviral against YFV is crucial, as there is no available effective drug against YFV. We have identified several novel nucleoside analogs with potent antiviral activity against YFV with 50% effective concentration (EC50) values between 0.25 and 1 μM with selectivity indices over 100 in culture.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Flaviviridaezzm321990; antiviral agents; nucleoside analogs; yellow fever virus

Mesh：

Substances：

Year:  2019        PMID： 31262759      PMCID： PMC6709485          DOI： 10.1128/AAC.00889-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2'-modified nucleotide analogues.

Authors:  Supanee Potisopon; François Ferron; Véronique Fattorini; Barbara Selisko; Bruno Canard
Journal:  Antiviral Res       Date:  2016-12-30       Impact factor: 5.970

Review 2.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Authors:  Alan D T Barrett; Dirk E Teuwen
Journal:  Curr Opin Immunol       Date:  2009-06-10       Impact factor: 7.486

3.  Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

Authors:  Claire Pierra; Agnès Amador; Samira Benzaria; Erika Cretton-Scott; Marc D'Amours; John Mao; Steven Mathieu; Adel Moussa; Edward G Bridges; David N Standring; Jean-Pierre Sommadossi; Richard Storer; Gilles Gosselin
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

4.  Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

5.  Characterization of the activity of 2'-C-methylcytidine against dengue virus replication.

Authors:  Jin-Ching Lee; Chin-Kai Tseng; Yu-Hsuan Wu; Neerja Kaushik-Basu; Chun-Kuang Lin; Wei-Chun Chen; Huey-Nan Wu
Journal:  Antiviral Res       Date:  2015-01-19       Impact factor: 5.970

6.  Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication.

Authors:  Jeremy L Clark; Laurent Hollecker; J Christian Mason; Lieven J Stuyver; Phillip M Tharnish; Stefania Lostia; Tamara R McBrayer; Raymond F Schinazi; Kyoichi A Watanabe; Michael J Otto; Phillip A Furman; Wojciech J Stec; Steven E Patterson; Krzysztof W Pankiewicz
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

7.  3',5'Di-O-trityluridine inhibits in vitro flavivirus replication.

Authors:  Tine De Burghgraeve; Barbara Selisko; Suzanne Kaptein; Grégory Chatelain; Pieter Leyssen; Yannick Debing; Michael Jacobs; Arthur Van Aerschot; Bruno Canard; Johan Neyts
Journal:  Antiviral Res       Date:  2013-03-05       Impact factor: 5.970

8.  Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.

Authors:  A H Cory; T C Owen; J A Barltrop; J G Cory
Journal:  Cancer Commun       Date:  1991-07

9.  2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.

Authors:  Shaoman Zhou; Sawsan Mahmoud; Peng Liu; Longhu Zhou; Maryam Ehteshami; Leda Bassit; Sijia Tao; Robert A Domaoal; Ozkan Sari; Coralie De Schutter; Sheida Amiralaei; Ahmed Khalil; Olivia Ollinger Russell; Tamara McBrayer; Tony Whitaker; Nageh Abou-Taleb; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  J Med Chem       Date:  2017-06-26       Impact factor: 7.446

10.  Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.

Authors:  Caroline S de Freitas; Luiza M Higa; Carolina Q Sacramento; André C Ferreira; Patrícia A Reis; Rodrigo Delvecchio; Fabio L Monteiro; Giselle Barbosa-Lima; Harrison James Westgarth; Yasmine Rangel Vieira; Mayara Mattos; Natasha Rocha; Lucas Villas Bôas Hoelz; Rennan Papaleo Paes Leme; Mônica M Bastos; Gisele Olinto L Rodrigues; Carla Elizabeth M Lopes; Celso Martins Queiroz-Junior; Cristiano X Lima; Vivian V Costa; Mauro M Teixeira; Fernando A Bozza; Patrícia T Bozza; Nubia Boechat; Amilcar Tanuri; Thiago Moreno L Souza
Journal:  PLoS Negl Trop Dis       Date:  2019-01-30
View more
  2 in total

1.  AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model.

Authors:  Kai Lin; Steven S Good; Justin G Julander; Abbie E Weight; Adel Moussa; Jean-Pierre Sommadossi
Journal:  PLoS Negl Trop Dis       Date:  2022-01-24

Review 2.  Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Authors:  Kay M Tomashek; Mark Challberg; Seema U Nayak; Helen F Schiltz
Journal:  Vaccines (Basel)       Date:  2019-11-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.